These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19147750)

  • 1. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Johnson BE; Jänne PA
    Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
    Sequist LV; Joshi VA; Jänne PA; Bell DW; Fidias P; Lindeman NI; Louis DN; Lee JC; Mark EJ; Longtine J; Verlander P; Kucherlapati R; Meyerson M; Haber DA; Johnson BE; Lynch TJ
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4403s-4408s. PubMed ID: 16857818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.
    Hoshi K; Takakura H; Mitani Y; Tatsumi K; Momiyama N; Ichikawa Y; Togo S; Miyagi T; Kawai Y; Kogo Y; Kikuchi T; Kato C; Arakawa T; Uno S; Cizdziel PE; Lezhava A; Ogawa N; Hayashizaki Y; Shimada H
    Clin Cancer Res; 2007 Sep; 13(17):4974-83. PubMed ID: 17785547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
    Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
    Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
    Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
    J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
    Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
    Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR FISH versus mutation: different tests, different end-points.
    Cappuzzo F
    Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
    Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
    Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HKI-272 in non small cell lung cancer.
    Wong KK
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4593-6. PubMed ID: 17671147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
    Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
    Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.